The Problem With Quality Collateral in the System

I think there's something to your what I'm suggesting here is somewhere in this mix. They have been bundling biotech securities into the derivatives tranches and those are traded largely privately. So they're shutting off the documents. This could be preparatory to your Putin 19 scenario. Would it be, would it be the companies? OrWould it be the people who now have the stuff in them? Good question. Because that's the more logical one.